Publications Angoiedèmes à kinines

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey.

Hereditary angioedema, emergency management of attacks by a call center.

Diagnostic biologique des angioedèmes bradykiniques : les recommandations du CREAK.

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey.

Bradykinin mechanism is the main responsible for death by isolated asphyxiating angioedema in France.

Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings

Efficacy of C1 inhibitor concentrate in hereditary angioedema with C1 inhibitor deficiency: Analysis in a French cohort.

Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families

Hereditary angioedema: Clinical presentation and socioeconomic cost of 200 French patients.

Repeated attacks of type III hereditary angioedema with factor XII mutation during pregnancy

Pediatricians diagnosed few patients with childhood-presented hereditary angioedema: Icatibant Outcome Survey findings.

Efficacy of C1 inhibitor concentrate in hereditary angioedema with C1 inhibitor deficiency: Analysis in a French cohort.

Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: Three additional French families. 

Hereditary Angioedema, Clinical Presentation and Socio-Economic Cost of 200 French Patients. 

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study.

Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial.

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight : findings from the Icatibant Outcome Survey, a cohort observational study. Caballero T et al. Clin Transl Allergy. 2018 Mar 23.
 
Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial. Javaud N et al. Ann Emerg Med. 2018 Mar.
 
Icatibant for ACE-inhibitor angioedema, an opportunity to treat the patients ? Javaud N et al. J Allergy Clin Immunol Pract. 2017 Nov – Dec.

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Aberer W et al. Allergy Asthma Clin Immunol. 2017 Jul 5;13:3.

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Caballero T et al. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1214-1222.

Normal PAI-2 level in French FXII-HAE patients. Marlu R et al. J Allergy Clin Immunol. 2017 May;139(5):1719-1720.

Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort. Bouillet L et al. Eur J Dermatol. 2017 Apr 1;27(2):155-159.